Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trends spotted in 2024’s crop of more than 150 series A rounds — from top therapeutic areas and modalities to the leading investors funding the innovation.The editors turn to Washington for takeaways from BioCentury’s “exit interview” with Patrizia Cavazzoni, the recently departed director of FDA’s Center for Drug Evaluation and Research, and checks in on FDA and NIH’s turbulent transition under Trump 2.0.Finally, the podcast team previews BioCentury’s upcoming fourth East-West Summit, which will focus on globalizing Asia innovation and the red-hot “Newco Model” in Singapore March 3-5, and the twenty-fifth Bio€quity Europe, which will be held in Belgium in May. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65483700:01 - Sponsor Message: ICON Biotech01:57 - Series As: Trends in Innovation12:18 - BioCentury Conferences Preview18:45 - Insights from FDA's Cavazzoni21:58 - Turbulence at FDA, NIHTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

There are no comments yet.

Please log in to write the first comment.